Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

@article{Berthold2005MyeloablativeMW,
  title={Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.},
  author={Frank Berthold and Joachim Boos and Stefan E. G. Burdach and Rudolf Erttmann and G{\"u}nter H R Henze and Johann Hermann and Thomas Klingebiel and Bernhard Kremens and Freimut H. Schilling and Martin Schrappe and Thorsten Simon and Barbara Hero},
  journal={The Lancet. Oncology},
  year={2005},
  volume={6 9},
  pages={649-58}
}
BACKGROUND Myeloablative megatherapy is commonly used to improve the poor outlook of children with high-risk neuroblastoma, yet its role is poorly defined. We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase event-free survival and overall survival compared with maintenance chemotherapy. METHODS 295 patients with high-risk neuroblastoma (ie, patients with stage 4 disease aged older than 1 year or those with MYCN-amplified tumours and stage 1, 2, 3… CONTINUE READING
129 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 129 extracted citations

Similar Papers

Loading similar papers…